Patent
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula I or a pharmaceutically acceptable salt thereof, wherein one of R 1 , R 2 , and R 3 is and of Formula IV or a pharmaceutically acceptable salt thereof.
1 . A compound that is
or a pharmaceutically acceptable salt thereof.
2 . A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
3 . A pharmaceutical composition for detecting mammalian tissue overexpressing prostate specific membrane antigen (PSMA), the composition comprising an effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
4 . The pharmaceutical composition of claim 3 , wherein the mammalian tissue comprises one or more of glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, and prostate cancer.
5 . A method comprising
administering a compound of claim 1 to a subject; and
subsequent to the administering, detecting one or more of positron emission, gamma rays from positron emission and annihilation, and Cerenkov radiation due to positron emission.
6 . The method of claim 5 , wherein the method comprises administering an effective amount of the compound to the subject.
7 . The method of claim 5 , wherein the subject is suspected of suffering from a mammalian tissue overexpressing prostate specific membrane antigen (PSMA).
8 . The method of claim 7 , wherein the mammalian tissue comprises one or more of glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, and prostate cancer.
9 . The method of claim 5 , wherein the administering the compound comprises parenteral administration.